Additional small molecules program for AMKD (Vertex Pharmaceuticals)

N/A

Report date: 2025/12/25 10:09:49
NME

Base Information

Drug NameAdditional small molecules program for AMKD (Vertex Pharmaceuticals)
Drug Alias NameAPOL1-mediated kidney disease therapy (Vertex Pharmaceuticals)AMKD therapy (Vertex Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApolipoprotein L1 inhibitors
TargetsApolipoprotein L1
Therapy Area/IndicationsKidney Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesVertex Pharmaceuticals Gmbh
Inactive CompaniesN/A
Active IndicationsKidney Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A